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Abstract
Background: Primary headache are prevalent and debilitating disorders. Acute pain cessation is one of the key
points in their treatment. Many drugs have been studied but the design of the trials is not usually homogeneous.
Efficacy of the trial is determined depending on the selected primary endpoint and usually other different
outcomes are measured. We aim to critically appraise which were the employed outcomes through a systematic
review.
Methods: We conducted a systematic review of literature focusing on studies on primary headache evaluating
acute relief of pain, following the PRISMA guideline. The study population included patients participating in a
controlled study about symptomatic treatment. The comparator could be placebo or the standard of care. The
collected information was the primary outcome of the study and all secondary outcomes. We evaluated the
studied drug, the year of publication and the type of journal. We performed a search and we screened all the
potential papers and reviewed them considering inclusion/exclusion criteria.
Results: The search showed 4288 clinical trials that were screened and 794 full articles were assessed for eligibility
for a final inclusion of 495 papers. The studies were published in headache specific journals (58%), general journals
(21.6%) and neuroscience journals (20.4%).
Migraine was the most studied headache, in 87.8% studies, followed by tension type headache in 4.7%. Regarding
the most evaluated drug, triptans represented 68.6% of all studies, followed by non-steroidal anti-inflammatories
(25.1%). Only 4.6% of the papers evaluated ergots and 1.6% analyzed opioids.
The most frequent primary endpoint was the relief of the headache at a determinate moment, in 54.1%. Primary
endpoint was evaluated at 2-h in 69.9% of the studies. Concerning other endpoints, tolerance was the most
frequently addressed (83%), followed by headache relief (71.1%), improvement of other symptoms (62.5%) and
presence of relapse (54%). The number of secondary endpoints increased from 4.2 (SD = 2.0) before 1991 to 6.39
after 2013 (p = 0.001).
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Conclusion: Headache relief has been the most employed primary endpoint but headache disappearance starts to
be firmly considered. The number of secondary endpoints increases over time and other outcomes such as
disability, quality of life and patients’ preference are receiving attention.
Keywords: Primary headaches, Clinical trials, Acute, Triptans, Non-steroidal anti-inflammatory, Prisma-guidelines,
Endpoints
Background
Primary headaches are the most prevalent neurological
disorders and the main neurological cause of years lived
with disability, particularly in the middle age group
under 50 years old adults, in which migraine is the first
cause of disability [1]. They represent also one of the
main neurological disorders regarding economical costs
[2], and symptomatic treatment accounts for the biggest
part of them [3].
Also for trials, success is a matter of perspective and
depends mainly on expectations. An intervention is con-
sidered efficacious if it reaches a predefined endpoint,
thus the careful definition of every endpoint is critical.
Not only concerning patients’ satisfaction and relief, but
also in order to reach the approval from the regulatory
authorities, such as the European Medicines Agency
(EMA) and the Food and Drug Administration (FDA).
In the field of headache, traditional endpoints in
chronic headaches have been related to the decrease in
number of days with headache, changes related to pain
intensity, analgesics uptake and emergency department
visits. Nowadays novel factors such as quality of life or
work absenteeism begin to be taken into account.
Regarding symptomatic therapies, many outcomes
have been proposed. The International Headache So-
ciety (IHS) created guidelines in order to harmonize
studies evaluating acute treatment. The first version
was published in 1991 [4], a second edition arrived
in 2000 [5] and the last dates from 2012 [6]. Every
edition added new proposed outcomes and instruc-
tions about how every endpoint should be measured.
Table 1 presents the list of outcomes mentioned in
the three versions of IHS Guidelines.
As shown in Table 1, the recommended main endpoint
has changed over time from headache relief to complete
pain freedom. This was motivated by the fact that pla-
cebo response in headache relief could be substantial,
over 30%, whereas pain freedom placebo response is just
around 9% [7]. Despite their utility, adherence to these
guidelines seemed to be low, just 31% of the studies
addressing acute treatment ascribed to them in the
2002–2008 period [8].
Table 1 Recommended endpoints from IHS guidelines for migraine drug trials according to the edition
1st edition (published in 1991) 2nd edition (published in 2000) 3rd edition (published in 2012)
Number of attacks resolved within 2h Pain-free after 2h Percentage of patients free of pain at 2h
Incidence of relapse
Duration of headache Sustained pain-free 24h Sustained pain freedom
Total migraine freedom
Severity of headache Headache intensity Intensity of headache
Global rating of attack severity Disability Headache relief
Time to meaningful relief
Time to pain freedom
Escape medication Rescue medication Rescue medication
Global evaluation of medication Global evaluation of medication Global evaluation of medication
Global impact (disability and quality of life)
Presence of nausea and vomiting Migraine-associated symptoms
Adverse events Adverse events
Patients preference Preference to treatment
Treatment of relapse
Consistency of effect.
In bold, the recommended primary endpoint
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Patient preference has received little and intermittent
attention. The triptan-era brought many studies trying
to assess what patients value most, and complete relief
of pain, a fast onset of action and lack of recurrence were
the preferred endpoints. Non-clinical endpoints such as
productivity, disability, direct costs, and quality of life have
also been considered recently [9], considering headache as
a multidimensional disease.
As we mentioned above, the criteria for success
have been defined by expert consensus, and patients’
opinions are not usually considered. The concept of
Patient Related Outcome Measure (PROM) defines
self-reported measures about symptoms, functional
status and perceptions from a patient perspective
[10]. This novel approach is receiving growing atten-
tion and identifying patients’ preferences might help
to create realistic outcomes, considering patients ex-
pectations [11, 12].
We aimed to critically appraise the employed out-
comes by conducting a systematic review. The study
population included patients with acute primary head-
ache; we considered all the possible interventions pur-
suing the resolution of the headache episode. Studies
employed placebo or the standard of care as compara-
tor. We analyzed every employed outcome.
Methods
We conducted a systematic review of literature focusing
on studies on primary headache addressing the acute
relief of pain, following the PRISMA guidelines [13].
Search criteria
The target population was primary headache sufferers,
the study population included patients participating in
a controlled study about the symptomatic treatment
for the relief of the headache episode. The interven-
tion was compared with placebo or the standard of care.
The collected information was the employed outcome of
the study, differentiating between primary and secondary
endpoints.
We did not restrict the search in time, considering
all available articles until the search. We reviewed
studies in all the European languages. Age of partici-
pants or the country in which the study took place
was not limited.
We included studies addressing the acute treatment
for primary headaches providing information about pri-
mary and secondary endpoints. The inclusion criteria
were: 1) clinical trials comparing with placebo or stand-
ard of care, 2) studies conducted in humans, 3) with full
text availability.
We excluded studies if they were: 1) not original re-
searches, 2) not focusing on treatment and addressing
other issues, 3) studying therapies that are not suitable
for self administration by patients, such as intravenous
therapies, 4) performed on emergency department set-
ting, 5) not providing information about the relief of
pain, 6) focused on secondary headaches.
Search strategy
The employed source was MEDLINE database. The
search was performed on April 22nd 2018 and included
all the studies. The electronic strategy of search was
designed in order to include the primary headaches and
all the possible acute therapies.
The strategy of search combined terms such as
primary headache, migraine, tension-type, trigeminal,
hemicrania, cluster, Short-lasting Unilateral neuralgi-
form headache with conjunctival injection and tearing
(SUNCT) and Short-lasting unilateral neuralgiform
headache attacks with cranial autonomic symptoms
(SUNA) by the use of boolean operators, combining
with the available therapies. We employed truncations
and wildcards to optimize the search. The employed
command is available in Appendix section. We included
common analgesics such as acetaminophen/paraceta-
mol or metamizol, non-steroidal anti-inflammatory
drugs (NSAIDs), triptans, anti-emetics (if employed for
pain relief), opioids, ergot derivatives, caffeine, magne-
sium, oxygen, devices that could be easily employed by
patients at home and novel drugs such as lasmiditan or
gepants, screening all the possible results.
Database creation and included variables
We created a database with all the potential studies.
Two investigators peer reviewed independently all the
abstracts and selected them according to inclusion and
exclusion criteria. Results were compared and in cases
with lack of agreement the rest of the team decided by
consensus if the study should be included or not. After
that, a different investigator reviewed the full document,
addressing the final eligibility if information about the
endpoint was provided and excluding the paper in the
opposite case.
As we were not specifically reviewing the results of the
interventions, we listed the different interventions con-
sidering the different primary and secondary outcomes
employed in each study, the year of publication and the
evaluated drug. We generated an electronic database
employing Microsoft Excel.
We considered the risk of publication bias so we in-
cluded only the information contained in the material
and methods section or in the study protocol, in order
to avoid lack of information. We tried to minimize the
bias of missing articles using a wide search strategy,
employing MeSH terms in the search and fully evaluat-
ing many of the papers in order to obtain firm evidence.
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Statistical description and analysis
We present the data as frequency for categorical vari-
ables and means and their standard deviation or me-
dians and Inter Quartile Range (IQR) for quantitative
data. For analytical purposes, we classified the jour-
nals into three groups: Headache specific journals,
neuroscience journals and general medicine journals.
All the journals included in each group can be con-
sulted in the Appendix. We also divided the time into
4 periods considering the date when the IHS official
guidelines for symptomatic studies were published,
being the intervals: before 1991, 1992–2000, 2001–
2012 and after 2013. We employed SPSS v20.0 IBM
for the statistical analysis employing the pertinent test
for each type and distribution of variable.
Results
We present the number of identified articles, those
screened and those that fulfilled inclusion and exclusion
criteria in the PRISMA flow chart (Fig. 1).
We included 495 papers in the final analysis. 58% of
the studies were published in headache specific journals,
20.4% in neuroscience journals and 21.6% in general
journals. The specific journals that showed most articles
were Headache with 156 papers, Cephalalgia with 112,
Neurology 36, European Neurology 19 and Journal of
Headache and Pain with 15.
Regarding the year of publication, the mode was 2005
and the median was 2003, with decreasing the number
of papers after 2010 (Fig. 2). The pattern of publication
differed comparing Headache Journals, which showed a
median year of publication of 2004 (IQR 1998–2009)
and general neurology journals, which had a median
year of 2003 (IQR 1997–2006) and general medicine
journals, whose distribution had a median of 2001 (IQR
1995–2007), p = 0.05. (Fig. 2).
Addressed headaches
The evaluated headache according IHS classification
were migraine in 87.8%, with 22 studies addressing
specifically menstrual migraine, 4.7% of the studies
were focused on tension type headache, 3.6% analyzed
trigeminoautonomal cephalalgias, 2 studies included
patients with both migraine and tension type and 19
studies mentioned primary headaches without additional
specifications. We did not find any trial on patients with
other primary headaches.
Studied drugs
The most frequently evaluated group of drugs was trip-
tans, representing 68.6% of the studies. Sumatriptan was
the most studied, counting 115 papers and representing
45,1% of the triptan articles, followed by rizatriptan (37
studies, 14.5%), zolmitriptan (33, 12.9%), almotriptan
(27, 10.8%), eletriptan (20, 7.8%), frovatriptan (10, 3.9%),
Fig. 1 PRISMA 2009 guidelines flow chart showing the flow of the search and analysis
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naratriptan (6, 2.4%), avitriptan (3, 1.2%) and 4 studies
did not specify the triptan clearly.
Non-steroidal anti-inflammatories were analyzed in
25,1% of the studies. Naproxen was the most frequently
evaluated, in 31 studies (26,9% of NSAID studies), followed
by acetylsalicylic acid in 27 (23.5%), ibuprofen in 17
(14.8%), diclofenac in 10 (8,7%) and dexketoprofen and
COX-2 inhibitors with 9 studies each (7.8%). Paracetamol
or acetaminophen were evaluated in 7.4% of the studies.
Only 4.6% of the papers analyzed ergots and 1.6% studied
opioids. Gepants were evaluated in 10 studies and only 1
Lasmiditan matched our criteria.
Up to 30.9% of the studies evaluated at least two different
analgesics, naproxen-sumatriptan being the most frequent
combination in 18 studies and dexketoprofen-frovatriptan
in 4. 70.6% of the studies included a placebo arm.
Figure 3 presents the number of publications per
5-year period differentiating the studied drug.
Primary endpoints
Concerning the primary endpoints, the most fre-
quent endpoint was the relief of the headache at a
determinate moment, representing 54.1% of the stud-
ies, followed by the complete disappearance of the
headache at a determinate time in 16.2% of the stud-
ies, subjective variables in 7.2%, the percentage of
patients with relief of the headache in 5,9%, total
migraine freedom in 5.3%, time to the pain free situ-
ation in 4.5% of the studies, tolerance and adverse
event presence in 3.1%, relapse of the headache in
1.2% of the papers, 1% focused on the accompanying
symptoms and 2.8% of the papers did not specified
clearly the primary endpoint. Figure 4 represents the
evolution of the primary endpoint over time, divided
in 5-year intervals and showing the percentage of
each primary endpoint in each time frame.
The time when the primary endpoint was evalu-
ated was 120 min in 69.9% of the studies. In studies
evaluating tension type headache and migraine, the
percentage ascended to 74.6%. 65.3% of the Neuro-
science journals analyzed the primary endpoint at
120 min, in comparison with 58.9% of the Headache
journals and 44.9% of the General Medicine journals
(p = 0.008). Figure 5 presents the percentage of stud-
ies that employed each time point in the evaluation
of the primary endpoint.
Secondary endpoints
Regarding the secondary endpoints of the studies, the per-
centage of studies that analyzed specifically each endpoint
is presented in the Fig. 6. The most frequently evaluated
was tolerance and adverse event presence followed by
headache relief and effect on other symptoms of the head-
ache different to the pain.
The number of endpoints that were addressed was
higher in headache specific journals, with a mean of
4.89 (SD = 2.1), followed by neuroscience journals
(4.56, SD = 1.8) and general medicine journals (4.23,
SD = 2.1), p = 0.01. That number also variated on
time, showing that studies published before the first
IHS recommendations included a mean of 4.20 (SD = 2.0)
recommendations; after that publication and before the
second edition (1991–2000) the mean number was 4.76
(SD = 1.9) and after the second IHS guidelines the mean
Fig. 3 Number of studies evaluating different pharmacological groups.
X-axis represents the time period and Y the number of studies
Fig. 2 Number of publications per year depending on the type of
journal. On the upper part, Headache specific journals, in the middle
Neurology journals and in the lower part General medicine journals.
Y-axis represent the number of publications and X-axis the year
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number was 4.5 (SD = 2.0) (2000–2012 period) and
after the publication of the third IHS guidelines (from
2013 to present) the mean number of fulfilled end-
points was 6.39 (SD = 2.1), (p = 0.001).
The percentage of studies that fulfilled all the IHS rec-
ommendations was of 10.8% for the first version, 8.2% for
the second version and 4.5% for the third one. Figure 7
represents the percentage of studies that analyzed each
efficacy endpoint over time. Endpoints evaluating func-
tionality were addressed in 33% of the studies. Patients’
preference was considered only in 4.98% of the stud-
ies and the global evaluation of the drug in 5.1% of
the papers.
Discussion
In this study, we systematically reviewed all the random-
ized controlled studies evaluating acute therapies for the
treatment of primary headaches. We addressed not only
which headaches and drugs under analysis, but also the
way they were evaluated, considering if IHS recommen-
dations were fulfilled.
The vast majority of the studies took place in mi-
graine patients. The low prevalence of other primary
headaches difficult its study in controlled trials,
nevertheless other prevalent conditions such as Ten-
sion Type Headache or Cluster Headache seem to
be underrepresented. In line with the previous find-
ing, migraine-specific therapies were the most fre-
quently studied. Triptans and NSAIDs aggregated
the majority of the studies, even when many other
analgesics are used in other painful conditions, most
of them have not been properly analyzed specifically
in headache.
The most frequently used main endpoint determin-
ing the success has been headache relief in the
majority of studies. We observed that recently, other
endpoints proposed by the IHS guidelines start to be
systematically addressed, specifically complete free-
dom of pain or disappearance of all migranous symp-
toms. Dealing with an exquisitely subjective condition
as pain could be hard. The wide inter-individual vari-
ability and the high risk of placebo effect, with the
subsequent possibility of false positive or false negative
results, are well-known. As IHS guidelines recommend, it
is desirable to employ total headache disappearance in-
stead of relief, as the improvement implicates considerable
subjectivity.
Two hours is the period defined as critical in the reso-
lution of the headache such as migraine or tension type
headache and most of the studies adhere to it. Only a
minority of studies employs the time to the disappear-
ance of the headache, probably because of the complex-
ity in its evaluation and a more complicated statistical
analysis. Many other endpoints were usually addressed,
mainly tolerance, effect on other symptoms associated
with the headache and relapse presence.
Fig. 4 Percentage of studies with a determinate primary endpoint per 5-year periods. Y-axis shows the percentages per each endpoint of the
total studies of each period, X-axis shows the different periods. AE = Adverse Events
Fig. 5 Percentage of studies evaluated at each determined time. X-
axis shows the predefined time points. Y-axis represents the number
of papers. Percentage of the total appears squared
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The number of studies clearly increases with the arrival
of the triptans, multiplying the number of publications in
a 10-fold in comparison with the pre-triptan era.
Sumatriptan is the most studied drug so far, present
in 23.2% of all the trials indexed in PubMed. In the
post-triptan era we have found a progressive decrease
of publication rate of studies, which could be in-
creased in the near future with the arrival of new
agents such as lasmiditan [14] and the gepants [15].
We have found also an increasing tendency over time
to publish in headache specific journals in comparison
with the past, when general medicine journals repre-
sented the preferred target for publication.
Concerning the cost, difficulty and bureaucracy
that conducting a randomized control trial (RCT)
implicates, many drugs that we use in our daily
practice have not been properly studied. Nowadays,
companies support most of the studies and “orphan”
drugs do not attract great interest. Something similar
can be noticed in headaches with a low prevalence,
in which the number of existing RCT’s is low or
even non-existent. In our study, almost 88% of the
studies were of migraine. Funding agencies and re-
searchers should be encouraged to evaluate drugs in
orphan indications as well.
One of the most surprising findings was the low
number of studies evaluating opioids, considering
how frequently patients employ them in the real
world studies. We only found 8 studies, representing
1,6% of all the studies. This could be partly explained
because 5 additional studies were excluded because
they took place in the Emergency Department Setting
or they implicated administration routes such as
intravenous or intramuscular. It is well known that
opioid consumption has been associated with chroni-
fication of some headaches and that they are consid-
ered one of the main causes of overuse of analgesics
[16, 17] nevertheless studies evaluating their efficacy
in headache relief and safety are surprisingly scarce.
Many of them were evaluated in combination with
other drugs, the majority employed improvement of
headache instead of headache relief and their adher-
ence to IHS guidelines was even lower. As far as this
study did not evaluate specifically results of the tri-
als, we cannot defend their use, which concerning
their potential risks, should be cautious until better
and newer studies take place.
Despite the fact that IHS published 3 editions of
the guidelines for studies evaluating symptomatic
treatment, most of the studies do not follow them
completely. Adherence to the guideline is important
not only because it assures the quality of the study
but also ensures comparability of data. For example,
the time when the main endpoint was evaluated was
Fig. 6 Percentage of studies that fulfilled each of the proposed endpoints. Blue represents articles that satisfied it and red the percentage of
studies that did not. AE: Adverse Events
Fig. 7 Percentage of studies addressing the recommended efficacy
endpoints per period, dividing X-axis in the periods pre-IHS
recommendations and after each version. Y-axis represents the
percentage of studies. Considered endpoints are: complete
headache resolution, headache relief, complete migraine resolution,
time to the improvement, and percentage of improved patients
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not 120 min in up to 30% of the studies. We found
a hopeful trend, as newer studies are conducted with
a closer adherence to guidelines, including a higher
number of endpoints and showing an increasing
percentage of efficacy endpoints being measured, es-
pecially in headache specific journals, which showed
statistically significant differences subscribing more
IHS guidelines. It may be truth that the burden of
headache is a frequent topic in headache journals;
nevertheless excellence in trial designs and reports
should be mandatory no matter the journal of
publication.
Considering the functional limitation and quality of
life impairment that most of the headaches implicate,
exploring the ability to work or act normally has also
been specifically evaluated. As primary headaches do not
implicate mortality, the morbidity and indirect cost due
to functional impairment is gaining attention, so ad-
dressing it specifically may give additional data of the
positive effect of a treatment. Only a third of the studies
considered this type of endpoints, so their presence still
should be increased.
Personal and social burden of headache disorders is
significant. Disability and health-related quality of life
have been increasingly used to help patient and clini-
cians make better decisions regarding headache treat-
ment and their presence in research tends to grow.
Novel tools are PROMs [18] that focus on patient per-
spective, therapeutic preference, and satisfaction with
treatments. PROMs may be an indirect indicator of ef-
ficacy, as patients will not probable feel satisfied with
inefficacious or poorly tolerated treatments [19].
Nevertheless, just 10% of the published studies consid-
ered these outcomes. IHS guidelines encourage au-
thors to employ them since the year 2000 [5] and they
represent one of the strategic objectives for research
in the European Community.
In line with our findings, studies fulfilling IHS guide-
lines reflect better the real efficacy of drugs. They em-
ploy more precise endpoints such as disappearance of
the headache; they focus on other headache symptoms
that can be as debilitating as the headache itself, and
they start taking into account other aspects related with
patient perspective. In our opinion, IHS guidelines
should be the reference in future studies addressing
headache specific treatments.
Concerning methodology, even though our study
does not analyze specifically data there is an inher-
ent risk of bias. Selection bias is possible if some
studies did not have a title or were under Mesh
classification. Further, in some cases it was difficult
to identify the main variable or the time when it
was evaluated. In those cases, we decided to leave
that variable empty, which happened in 2.6% of the
studies for the primary endpoint and 18.2% of the
studies concerning the temporal evaluation. However,
we believe the impact of this to be minimal on the
final results.
Conclusion
Headache relief has been the most employed primary
endpoint; nevertheless, as IHS guidelines recommend,
better efficacy endpoints like headache disappearance
start to be preferred. We found a promising increase in
the number of secondary endpoints, considering also
disability, quality of life and patients’ preference, so fu-
ture studies should subscribe them in order to warrant
quality and homogeneity.
Triptans completely changed the panorama in symp-
tomatic drug studies and their arrival improved the way
RCTs are conducted in headache, nevertheless studies
should subscribe guidelines in order to allow compar-
ability as well.
To date, most of the studies took place in migraine
patients but analyzing a small proportion of all the
available drugs. In the future, orphan drugs and drugs
with insufficient information, such as opioids, should
be also evaluated and other prevalent and rare condi-
tions should be studied in a randomized controlled
setting.
Appendix I
Command employed in the search.
(((((((((((primary headache*) OR primary headache disor-
der[MeSH Terms]) OR migraine) OR tension-type) OR
trigeminal) OR hemicrania) OR cluster) OR sunct) OR
suna) OR ""Short Lasting Unilateral Neuralgiform Head-
ache Attacks"")) AND ((((((((telcagepant) OR ubrogepant)
OR Olcegepant) OR gepant*)) OR (((((""Anti-Inflammatory
Agents, Non-Steroidal""[Mesh]) OR (((((((((((((((((((na-
proxen*) OR aspirin*) OR salicylic*) OR salicylic) OR
((paracetamol*) OR paracetamol)) OR acetaminophen*) OR
((indomethacin*) OR Indomethacin)) OR ((dexketoprofen)
OR dexketoprophen)) OR celecoxib*) OR rofecoxib*) OR
diclophenac) OR ketoprofen*) OR ketorolac*) OR ibupro-
fen*) OR Excedrin) OR Perdolan) OR Dafalgan) OR
Lonarid) OR Panadol))) OR (((((((((((domperidone) OR
metoclopramide*) OR ((metamizol*) OR metamizol)) OR
((codein*) OR codeine)) OR tramadol*) OR morphin*) OR
oxycodon*) OR ergot*) OR ergot) OR triptan*) OR trip-
tan)) OR ((((lasmiditan) OR caffein*) OR magnesium*)
OR ((oxygen*) OR oxygen))))) OR (((((((((((Pulsante)
OR gammacore) OR Transcranial direct-current sti-
mul*) OR springTMS) OR cefaly) OR transcranial mag-
netic stimul*) OR vagal nerve stimul*) OR Sphenopalatine
Ganglion Stimul*) OR caloric vestibular stimul*) OR
Occipital nerve stimul*) OR Transcutaneous Supraorbital
Neuro Stimul*)
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Appendix II
Table 2 Name of the journal according to each group
Kind of Journal Total
Headache J Neuro J General J
Acta Neurol Scand 0 3 0 3
Adv Ther 0 0 1 1
Am J Emerg Med 0 0 3 3
Am J Med 0 0 1 1
Ann Emerg Med 0 0 3 3
Ann Neurol 0 1 0 1
Arch Intern Med 0 0 2 2
Arch Neurol 0 7 0 7
Arq Neuropsiquiatr 0 1 0 1
BMC Neurol 0 1 0 1
Br J Clin Pharmacol 0 0 1 1
Br J Prev Soc Med 0 0 1 1
Br Med J 0 0 1 1
Br Med J (Clin Res Ed) 0 0 1 1
Brain Res Bull 0 1 0 1
Cephalalgia 112 0 0 112
Clin Drug Investig 0 0 1 1
Clin Neuropharmacol 0 1 0 1
Clin Pharmacol Ther 0 0 2 2
Clin Ther 0 0 16 16
CNS Drugs 0 5 0 5
Curr Med Res Opin 0 0 12 12
Drug Dev Ind Pharm 0 0 1 1
Drug Ther Bull 0 0 1 1
Drugs 0 0 1 1
Eur J Neurol 0 8 0 8
Eur J Pain 0 1 0 1
Eur Neurol 0 19 0 19
Expert Rev. Clin Pharmacol 0 0 1 1
Expert Rev. Neurother 0 1 0 1
Gynecol Endocrinol 0 0 1 1
Headache 156 0 0 156
Heart Dis 0 0 1 1
Int J Clin Pract 0 0 3 3
Int J Neurosci 0 1 0 1
Intern Med 0 0 1 1
J Chin Med Assoc 0 0 1 1
J Clin Pharmacol 0 0 1 1
J Clin Pharmacol J New Drugs 0 0 1 1
J Coll Gen Pract 0 0 1 1
J Emerg Med 0 0 1 1
J Headache Pain 15 0 0 15
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J Pharm Pharmacol 0 0 1 1
JAMA 0 0 4 4
Lancet 0 0 6 6
Lancet Neurol 0 3 0 3
Mayo Clin Proc 0 0 3 3
MedGenMed 0 0 3 3
N Engl J Med 0 0 2 2
Neurol Sci 0 9 0 9
Neurology 0 36 0 36
Obstet Gynecol 0 0 4 4
Pain Med 1 0 0 1
Pain Physician 1 0 0 1
Pain Pract 1 0 0 1
Pediatr Neurol 0 1 0 1
Pediatrics 0 0 3 3
Pharmacoeconomics 0 0 5 5
Phytother Res 0 0 1 1
Postgrad Med 0 0 1 1
Postgrad Med J 0 0 1 1
QJM 0 0 1 1
Sci Transl Med 0 0 1 1
Singapore Med J 0 0 1 1
Value Health 0 0 2 2
Total 287 101 107 495
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Iranian Center of Neurological Research Neuroscience Institute, Tehran
University of Medical Sciences, Tehran, Iran. 4Child Neuropsychiatry School,
University of Palermo, Palermo, Italy. 5U.O. Neuropsychiatry - ARNAS Civico,
PO Di Cristina, Palermo, Italy. 6Neurology Department, University Hospital of
Brussels, Brussels, Belgium. 7Headache Center, Bambino Gesù Children
Hospital IRCCS, Rome, Italy. 8Pavlov First Saint Petersburg State Medical
University, Saint Petesburg, Russia. 9Almazov National Medical Research
Centre, Saint Petesburg, Russia. 10Internal Medicine Department, Sant’Andrea
Hospital, Rome, Italy. 11Regional Referral Headache Centre, Sant’Andrea
Hospital, Department of Clinical and Molecular Medicine, Sapienza University,
Rome, Italy. 12Headache Centre, Careggi University Hospital, University of
Florence, Florence, Italy. 13Danish Headache Center, Department of
Neurology, Rigshospitalet-Glostrup, University of Copenhagen, Copenhagen,
Denmark. 14Department of Clinical Physiology and Nuclear Medicine, Center
for Functional and Diagnostic Imaging, Hvidovre Hospital, Copenhagen,
Denmark.
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